pharmaphorum4d
Kelun's MSD-partnered TROP2 drug gets first okay in China
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).
Pharmabiz1mon
Kelun-Biotech’s novel ADC drug SKB445 receives NMPA approval to treat advanced solid tumours
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a holding subsidiary of Kelun Pharmaceutical, announced that the company has received a clinical trial notice approving the investigational new drug ...
Morningstar1mon
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
Morningstar brands and products Company Portfolio ...
Yahoo Finance1mon
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and safety results from the Phase 1/2 KL264-01/MK-2870-001 study (NCT04152499) of its anti-TROP2 ADC ...